Log In or Create Account

CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact

Advanced Search

CME Courses
CME Webinars
Dialogues
Topics In Antiviral Medicine
HIV Drug Resistance
Fellow Resources
About

James Raper, PhD, DSN, CRNP, JD

James Raper

James Raper, PhD, DSN, CRNP, JD

Professor of Medicine and Nursing

University of Alabama at Birmingham

Birmingham, AL

131 Steuart St, Suite 500, San Francisco, CA 94105

Phone: (415) 544-9400 | info@iasusa.org

Home
Activities
Resources
About
Contact
Login
Careers
Donate
Website Policies

© 2026 International Antiviral Society–USA. All Rights Reserved.

CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact
CME Courses
CME Webinars
Dialogues
Topics In Antiviral Medicine
HIV Drug Resistance
Fellow Resources
About

Practice Question of the Week

June 8, 2026: HBV Reactivation During Tenofovir-Sparing ART

Which of the following statements is correct regarding the risk for hepatitis B virus (HBV) reactivation during tenofovir-sparing antiretroviral therapy (ART)?
- A. Reactivation does not occur in individuals with documented positive hepatitis B surface antibody (HBsAb)
- B. Reactivation should not occur if lamivudine (3TC) or emtricitabine (FTC) are included in the regimen
- C. HBV DNA elevation that occurs during reactivation can resolve without resumption of tenofovir
- D. Quantitative hepatitis B core antibody (HBcAb) titers predict the risk of HBV reactivation

View the Presentation

View the On-Demand Course

View Archived Questions